Davide Chiesi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Davide Chiesi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Monika E. Hegi
Lausanne University Hospital and University of Lausanne
3 shared publications Carla Mendes Ferreira
Lundin Family Brain Tumor Research Center, Departments of Oncology and Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne Switzerland
2 shared publications- Pierre Bady
Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne , Lausanne
2 shared publications - Alessandro Tancredi
Neuroscience Research Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
1 shared publication - Kedir S Mohammed
Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne , Lausanne
1 shared publication Kedir S. Mohammed
Neuroscience Research Center and Neurosurgery, Lausanne Univerisity Hospital and University of Lausanne, Lausanne, Switzerland
1 shared publication
Latest Publications
- Open Access
Leveraging epigenetic vulnerabilities of the stem cell-related HOX-signature in glioblastoma
Background: Glioblastoma (GB) is the most aggressive primary brain tumor, characterized by therapy resistance, attributed to a multitude of epi-genetic changes resulting in phenotypic plasticity with altered cell states. To uncover druggable epigenetic vulnerabilities, we disturbed GB-derived spheres and observed coordinated repression of the aberrantly activated hemopoietic stem-like cell signature, dominated by HOX genes. This signature has been associated with poor prognosis and resistance to therapy in GB. Here we investigate biological vulnerabilities associated with the deregulated epigenetic landscape in high- HOX GB. Methods: GB-derived spheres (GS) were treated with an inhibitor of Bromodomain and extra-terminal motif proteins (BETi) (JQ1) or transduced with inducible constructs to genetically modulate HOXA10 expression (shRNA for knockdown, ectopic HOXA10 ). Functional effects were evaluated through proliferation, neurosphere formation, and senescence assays. Epigenomic profiling incorporated RNA-seq, ChIP-seq, ATAC-seq, promoter capture MicroC, and DNA methylation. Results: BETi-mediated rapid, coordinated downregulation of the HOX -signature, suggested direct transcriptional regulation. Knockdown of HOXA10 alone yielded similar effects, decreasing expression of HOX genes, reducing proliferation, self-renewal capacity, and triggering senescence. Conversely, ectopic HOXA10 expression was ineffective in reactivating the HOX cluster, or reverse BETi-mediated biological effects. Integrative epigenomic analysis of high- HOX -GS revealed concerted activation of the HOX region, with broad domains of H3K27ac/H3K4me3 associated with super-enhancer activity, open chromatin (ATAC) and focal DNA hypomethylation. Architectural changes included altered CTCF interactions and increased promoter-anchored looping. Conclusion: These results position the HOX -signature as a potential therapeutic target and offer a mechanistic rationale for disrupting BET-dependent transcriptional regulation in high- HOX GB.
Open AccessLeveraging epigenetic vulnerabilities of the stem cell-related HOX-signature in glioblastoma
Background: Glioblastoma (GB) is the most aggressive primary brain tumor, characterized by therapy resistance, attributed to a multitude of epi-genetic changes resulting in phenotypic plasticity with altered cell states. To uncover druggable epigenetic vulnerabilities, we disturbed GB-derived spheres and observed coordinated repression of the aberrantly activated hemopoietic stem-like cell signature, dominated by HOX genes. This signature has been associated with poor prognosis and resistance to therapy in GB. Here we investigate biological vulnerabilities associated with the deregulated epigenetic landscape in high- HOX GB. Methods: GB-derived spheres (GS) were treated with an inhibitor of Bromodomain and extra-terminal motif proteins (BETi) (JQ1) or transduced with inducible constructs to genetically modulate HOXA10 expression (shRNA for knockdown, ectopic HOXA10 ). Functional effects were evaluated through proliferation, neurosphere formation, and senescence assays. Epigenomic profiling incorporated RNA-seq, ChIP-seq, ATAC-seq, promoter capture MicroC, and DNA methylation. Results: BETi-mediated rapid, coordinated downregulation of the HOX -signature, suggested direct transcriptional regulation. Knockdown of HOXA10 alone yielded similar effects, decreasing expression of HOX genes, reducing proliferation, self-renewal capacity, and triggering senescence. Conversely, ectopic HOXA10 expression was ineffective in reactivating the HOX cluster, or reverse BETi-mediated biological effects. Integrative epigenomic analysis of high- HOX -GS revealed concerted activation of the HOX region, with broad domains of H3K27ac/H3K4me3 associated with super-enhancer activity, open chromatin (ATAC) and focal DNA hypomethylation. Architectural changes included altered CTCF interactions and increased promoter-anchored looping. Conclusion: These results position the HOX -signature as a potential therapeutic target and offer a mechanistic rationale for disrupting BET-dependent transcriptional regulation in high- HOX GB.
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Bromodomain and extra-terminal motif (BET) inhibition induces coordinated repression of the stem cell-related HOX signature in glioblastoma uncovering an epigenetic vulnerability
Background: Glioblastoma (GB) is the most aggressive primary brain tumor, characterized by therapy resistance, attributed to a multitude of epigenetic changes resulting in phenotypic plasticity with altered cell states. To uncover druggable epigenetic vulnerabilities, we disturbed GB-derived spheres with an inhibitor of Bromodomain and extra-terminal motif proteins (BETi) and observed coordinated repression of the aberrantly activated hemopoietic stem-like cell signature, dominated by HOXA genes. This signature has been associated with poor prognosis and resistance to therapy in GB. Here we investigate the deregulated epigenetic landscape and potential vulnerabilities in high-HOX GB. Methods: GB-derived spheres (GS) were treated with the BETi (JQ1) or transduced with inducible constructs to genetically modulate HOXA10 expression short-hairpin (sh)RNA for knockdown, ectopic HOXA10). Functional effects were evaluated through proliferation, neurosphere formation, and senescence assays. Epigenomic profiling incorporated RNA-seq, Chromatin Immuno Precipitation sequencing (ChIP-seq), Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq), promoter capture MicroC, and DNA methylation. Results: BETi-mediated rapid, coordinated downregulation of the HOX-signature suggested direct transcriptional regulation. Knockdown of HOXA10 alone yielded similar effects, decreasing expression of HOXA genes, reducing proliferation, self-renewal capacity, and triggering senescence. Conversely, ectopic HOXA10 expression failed to reactivate the HOXA cluster or reverse BETi-mediated biological effects. Integrative epigenomic analysis of high-HOX-GS revealed concerted activation of the HOXA region, with broad domains of H3K27ac/H3K4me3 associated with super-enhancer activity, open chromatin (ATAC), and focal DNA hypomethylation. Architectural changes included altered CCCTC-binding factor (CTCF) interactions and increased promoter-anchored looping. Conclusion: These results position the HOX-signature as a potential therapeutic target and offer a mechanistic rationale for disrupting BET-dependent transcriptional regulation in high-HOX GB.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessBromodomain and extra-terminal motif (BET) inhibition induces coordinated repression of the stem cell-related HOX signature in glioblastoma uncovering an epigenetic vulnerability
Background: Glioblastoma (GB) is the most aggressive primary brain tumor, characterized by therapy resistance, attributed to a multitude of epigenetic changes resulting in phenotypic plasticity with altered cell states. To uncover druggable epigenetic vulnerabilities, we disturbed GB-derived spheres with an inhibitor of Bromodomain and extra-terminal motif proteins (BETi) and observed coordinated repression of the aberrantly activated hemopoietic stem-like cell signature, dominated by HOXA genes. This signature has been associated with poor prognosis and resistance to therapy in GB. Here we investigate the deregulated epigenetic landscape and potential vulnerabilities in high-HOX GB. Methods: GB-derived spheres (GS) were treated with the BETi (JQ1) or transduced with inducible constructs to genetically modulate HOXA10 expression short-hairpin (sh)RNA for knockdown, ectopic HOXA10). Functional effects were evaluated through proliferation, neurosphere formation, and senescence assays. Epigenomic profiling incorporated RNA-seq, Chromatin Immuno Precipitation sequencing (ChIP-seq), Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq), promoter capture MicroC, and DNA methylation. Results: BETi-mediated rapid, coordinated downregulation of the HOX-signature suggested direct transcriptional regulation. Knockdown of HOXA10 alone yielded similar effects, decreasing expression of HOXA genes, reducing proliferation, self-renewal capacity, and triggering senescence. Conversely, ectopic HOXA10 expression failed to reactivate the HOXA cluster or reverse BETi-mediated biological effects. Integrative epigenomic analysis of high-HOX-GS revealed concerted activation of the HOXA region, with broad domains of H3K27ac/H3K4me3 associated with super-enhancer activity, open chromatin (ATAC), and focal DNA hypomethylation. Architectural changes included altered CCCTC-binding factor (CTCF) interactions and increased promoter-anchored looping. Conclusion: These results position the HOX-signature as a potential therapeutic target and offer a mechanistic rationale for disrupting BET-dependent transcriptional regulation in high-HOX GB.
- Open Access
- 13 December 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (12) , 1-12
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Bromodomain and extra-terminal tail (BET) proteins have been identified as potential epigenetic targets in cancer, including glioblastoma. These epigenetic modifiers link the histone code to gene transcription that can be disrupted with small molecule BET inhibitors (BETi). With the aim of developing rational combination treatments for glioblastoma, we analyzed BETi-induced differential gene expression in glioblastoma derived-spheres, and identified 6 distinct response patterns. To uncover emerging actionable vulnerabilities that can be targeted with a second drug, we extracted the 169 significantly disturbed DNA Damage Response genes and inspected their response pattern. The most prominent candidate with consistent downregulation, was the O-6-methylguanine-DNA methyltransferase (MGMT) gene, a known resistance factor for alkylating agent therapy in glioblastoma. BETi not only reduced MGMT expression in GBM cells, but also inhibited its induction, typically observed upon temozolomide treatment. To determine the potential clinical relevance, we evaluated the specificity of the effect on MGMT expression and MGMT mediated treatment resistance to temozolomide. BETi-mediated attenuation of MGMT expression was associated with reduction of BRD4- and Pol II-binding at the MGMT promoter. On the functional level, we demonstrated that ectopic expression of MGMT under an unrelated promoter was not affected by BETi, while under the same conditions, pharmacologic inhibition of MGMT restored the sensitivity to temozolomide, reflected in an increased level of γ-H2AX, a proxy for DNA double-strand breaks. Importantly, expression of MSH6 and MSH2, which are required for sensitivity to unrepaired O6-methylguanine-lesions, was only briefly affected by BETi. Taken together, the addition of BET-inhibitors to the current standard of care, comprising temozolomide treatment, may sensitize the 50% of patients whose glioblastoma exert an unmethylated MGMT promoter.
- 13 December 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (12) , 1-12
Open AccessBET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Bromodomain and extra-terminal tail (BET) proteins have been identified as potential epigenetic targets in cancer, including glioblastoma. These epigenetic modifiers link the histone code to gene transcription that can be disrupted with small molecule BET inhibitors (BETi). With the aim of developing rational combination treatments for glioblastoma, we analyzed BETi-induced differential gene expression in glioblastoma derived-spheres, and identified 6 distinct response patterns. To uncover emerging actionable vulnerabilities that can be targeted with a second drug, we extracted the 169 significantly disturbed DNA Damage Response genes and inspected their response pattern. The most prominent candidate with consistent downregulation, was the O-6-methylguanine-DNA methyltransferase (MGMT) gene, a known resistance factor for alkylating agent therapy in glioblastoma. BETi not only reduced MGMT expression in GBM cells, but also inhibited its induction, typically observed upon temozolomide treatment. To determine the potential clinical relevance, we evaluated the specificity of the effect on MGMT expression and MGMT mediated treatment resistance to temozolomide. BETi-mediated attenuation of MGMT expression was associated with reduction of BRD4- and Pol II-binding at the MGMT promoter. On the functional level, we demonstrated that ectopic expression of MGMT under an unrelated promoter was not affected by BETi, while under the same conditions, pharmacologic inhibition of MGMT restored the sensitivity to temozolomide, reflected in an increased level of γ-H2AX, a proxy for DNA double-strand breaks. Importantly, expression of MSH6 and MSH2, which are required for sensitivity to unrepaired O6-methylguanine-lesions, was only briefly affected by BETi. Taken together, the addition of BET-inhibitors to the current standard of care, comprising temozolomide treatment, may sensitize the 50% of patients whose glioblastoma exert an unmethylated MGMT promoter.